Halozyme Therapeutics, Inc. (HALO) Stock

Halozyme Therapeutics, Inc. operates as a biopharmaceutical technology platform company with a global presence spanning the United States, Switzerland, Ireland, Belgium, Japan, and beyond. At the core of its offerings is the ENHANZE drug delivery technology, centered around a patented recombinant human hyaluronidase enzyme (rHuPH20). This technology enables the subcutaneous administration of injectable biologics, including monoclonal antibodies, therapeutic molecules, small molecules, and fluids, facilitating enhanced patient convenience and treatment efficacy.

The company's flagship product, Hylenex recombinant, leverages rHuPH20 to improve subcutaneous fluid administration for hydration, thereby enhancing the dispersion and absorption of other injected drugs used in subcutaneous urography and aiding the resorption of radiopaque agents. Halozyme Therapeutics, Inc. also advances a robust pipeline of therapies. This includes partnerships with prominent pharmaceutical companies to develop and commercialize treatments such as Perjeta, RITUXAN HYCELA, MabThera SC, and HYQVIA for various immunodeficiency disorders, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.

Beyond these, Halozyme Therapeutics, Inc. is actively involved in the development of additional therapies. These include Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, DARZALEX for amyloidosis and multiple myeloma, as well as other treatments targeting solid tumors and autoimmune diseases. The company collaborates extensively with industry leaders like F. Hoffmann-La Roche, Pfizer, Janssen Biotech, Eli Lilly, Bristol-Myers Squibb, and many others to advance therapeutic solutions across diverse medical needs.

Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics, Inc. continues to drive innovation in biopharmaceuticals through its pioneering drug delivery technologies and strategic collaborations. With a commitment to enhancing treatment outcomes and patient experiences, the company remains at the forefront of transforming the landscape of therapeutic delivery and development worldwide.